Kaleido Biosciences, Inc. Common Stock
KLDO
KLDO was delisted on the 14th of April, 2022.
66 hedge funds and large institutions have $80.8M invested in Kaleido Biosciences, Inc. Common Stock in 2021 Q4 according to their latest regulatory filings, with 10 funds opening new positions, 20 increasing their positions, 16 reducing their positions, and 14 closing their positions.
552% more call options, than puts
Call options by funds: $574K | Put options by funds: $88K
25% more repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 16
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
7% less funds holding
Funds holding: 71 → 66 (-5)
29% less first-time investments, than exits
New positions opened: 10 | Existing positions closed: 14
57% less capital invested
Capital invested by funds: $190M → $80.8M (-$109M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$512K |
| 2 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
+$254K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$185K |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$90.7K |
| 5 |
E
Ergoteles
New York
|
+$79.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PAI
Palo Alto Investors
Palo Alto,
California
|
-$1.81M |
| 2 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$891K |
| 3 |
BlackRock
New York
|
-$704K |
| 4 |
IC
Ikarian Capital
Dallas,
Texas
|
-$546K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
-$147K |
KLDO Hedge Fund Activity: Q4 2021 in Review
66 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Kaleido Biosciences, Inc. Common Stock (KLDO) for Q4 2021, worth a combined $80.8M — down 57% from $190M a quarter earlier.
Sellers outnumbered buyers: 14 funds closed out of KLDO and 10 opened new positions — a net loss of 4 holders — while 16 trimmed existing stakes and 20 added.
The largest buyer was Millennium Management, opening a new position worth an estimated $512K. The largest seller was Palo Alto Investors, cutting an estimated $1.81M.
- 66 institutional investors held Kaleido Biosciences, Inc. Common Stock (KLDO) as of Q4 2021, down from 71 in Q3 2021.
- Funds reported $80.8M of Kaleido Biosciences, Inc. Common Stock stock for Q4 2021, down 57% quarter-over-quarter.
- 10 funds opened new Kaleido Biosciences, Inc. Common Stock positions in Q4 2021 and 14 closed out, a net change of -4 holders.
- The largest Kaleido Biosciences, Inc. Common Stock buyer in Q4 2021 was Millennium Management, an estimated $512K added.
- The largest Kaleido Biosciences, Inc. Common Stock seller in Q4 2021 was Palo Alto Investors, an estimated $1.81M sold.
Based on aggregated 13F filings for Q4 2021.